乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床效果观察

目的观察乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床效果。方法参选由本院接受治疗急性胰腺炎患者54例,按入院先后均分成对照组患者27例和治疗组患者27例。对照组单一给药奥曲肽治,治疗组采用乌司他丁联合奥曲肽给药治疗,观察并比较临床疗效。结果治疗组的治疗效果达到96.01%,显著高于对照组的76.03%,治疗组不良反应率4.81%,显著低于对照组的5.91%,停药后不良反应可自行恢复,治疗组检验指标尿淀粉酶和血淀粉酶恢复率也显著高于对照组,比较差异显著,P <0.05。结论单用奥曲肽治疗急性胰腺炎效果没有乌司他丁联合奥曲肽用药诊治急性胰腺炎疗效显著,值得临床推广。     

奥曲肽联合前列地尔治疗急性胰腺炎的临床疗效

目的探讨奥曲肽联合前列地尔治疗急性胰腺炎的临床疗效。方法选取2012年10月至2014年10月我院收治的急性胰腺炎患者62例作为临床研究对象,使用随机数字列表将其随机分为研究组和对照组。对照组27例患者单纯采用奥曲肽进行治疗,研究组35例患者在对照组的基础上加用前列地尔进行治疗。治疗后观察两组患者的临床疗效,并进行对比分析。结果研究组患者治疗的总有效率(97.2%)明显高于对照组(77.9%),(P<0.05)差异均有统计学意义。结论对急性胰腺炎患者采用奥曲肽联合前列地尔进行治疗具有良好的临床疗效,值得在临床上进一步推广。     

38例高脂血症性急性胰腺炎的临床治疗分析

目的探讨高脂血症性急性胰腺炎的临床治疗方法和效果。方法选取我院收治38例高脂血症性急性胰腺炎患者为研究对象,随机分为对照组和治疗组,对照组19例采用常规禁食、胃肠减压、抗感染、制酸以及液体复苏、控制血糖、奥曲肽、奥美拉唑治疗,治疗组19例在此基础上,静脉滴注前列地尔注射液。结果治疗组总有效率高达94.7%,对照组总两组总有效率比较差异显著(P<0.05);治疗组在临床症状、体征及血淀粉酶缓解情况比较上,各项指标均优于对照组(P<0.05)。结论在使用奥曲肽和奥美拉唑的基础上联合采用前列地尔,能够提高患者治愈率,缩短治疗时间,可以在临床上推广应用。     

奥曲肽联合前列地尔治疗急性胰腺炎患者的效果评价

目的 评价奥曲肽联合前列地尔治疗急性胰腺炎(AP)的效果.方法 将本院2014年1月至2015年6月收治的56例AP患者以随机数字法分为对照组和观察组,每组28例.对照组奥曲肽治疗,观察组奥曲肽联合前列地尔治疗.比较两组临床疗效.结果 观察组腹痛消失时间[(4.87±1.06)d vs.(7.18± 1.15)d]、胃肠减压时间[(6.14±1.61)d vs.(9.26±1.88)d]、血清淀粉酶正常时间[(3.83±1.01)d vs.(6.76±1.57)d]及住院天数[(9.32±3.45)d vs.(20.41±3.92)d]均显著低于对照组(P＜0.05);观察组愈显率92.86％,明显高于对照组的67.86％(P＜0.05).结论 奥曲肽联合前列地尔可有效缩短AP患者治疗时间,提高临床疗效,促进患者恢复,且无明显用药反应,是一种安全有效的治疗方案.     

乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床疗效分析

目的：分析研究乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床疗效。方法将61例重症急性胰腺炎患者随机分为观察组36例和对照组25例,对照组患者给予奥曲肽治疗,观察组在对照组的基础上给予乌司他丁治疗,观察两组临床疗效及不良反应情况。结果观察组总有效率明显高于对照组总有效率（P〈0.05）。结论乌司他丁联合奥曲肽治疗重症急性胰腺炎能有效提高临床疗效。     

乌司他丁联合奥曲肽治疗重症急性胰腺炎的临床效果观察

目的:观察重症急性胰腺炎使用乌司他丁联合奥曲肽治疗的临床疗效.方法:选取浙江省杭州市萧山区第一人民医院2014年10月~2016年10月收治的84例重症急性胰腺炎患者,利用完全随机分配法分为观察组(42例)和对照组(42例).对于对照组单纯采用乌司他丁治疗,观察组采用乌司他丁联合奥曲肽治疗,比较两组治疗效果.结果:与对照组比较,观察组血、尿淀粉酶恢复时间明显缩短,腹痛缓解时间与平均住院时间明显减少,具有显著差异(均P<0.01).观察组的总有效率92.8%,对照组的总有效率78.6%,两组差异具有统计学意义(X2=6.57,P<0.05).观察组的不良反应发生率9.5%,明显低于对照组的不良反应发生率23.8%,差异具有统计学意义(X2=3.78,P<0.05).结论:乌司他丁联合奥曲肽治疗重症急性胰腺炎临床效果显著,可有效缓解临床症状,减少不良反应,值得临床推广.     

奥曲肽联合中药治疗轻型急性胰腺炎的临床分析

目的探讨奥曲肽联合中药治疗轻型急性胰腺炎的临床疗效。方法对本院收治的72例轻型急性胰腺炎患者随机分为观察组和对照组,观察组患者使用奥曲肽联合中药治疗,对照组患者使用常规的方法治疗。结果观察组临床疗效总有效率为91.7%,对照组临床疗效总有效率为77.8%,观察组的临床疗效明显高于对照组患者（P〈0.05）。结论奥曲肽联合中药治疗轻型急性胰腺炎取得的临床疗效显著。     

乌司他丁联合奥曲肽治疗急性重症胰腺炎的临床研究

目的分析乌司他丁联合奥曲肽治疗急性重症胰腺炎的疗效。方法采取随机抽签的方式将我院在2016年6月至2018年6月收治的66例急性重症胰腺炎患者分为联合组(33例)与对照组(33例),联合组采取乌司他丁+奥曲肽治疗,对照组采取奥曲肽治疗,对比两组患者的治疗效果、临床指标、不良反应发生率。结果联合组患者治疗总有效率(93.9%)较对照组(75.8%)更高,腹痛缓解时间、胃肠减压时间、血淀粉酶恢复时间、住院时间较对照组更短,组间比较P <0.05;两组患者不良反应发生率较为接近,组间比较P> 0.05。结论对急性重症胰腺炎患者给予乌司他丁联合奥曲肽治疗可取得较好的临床疗效,且不良反应较少,值得在临床中推广应用。     

乌司他丁联合奥曲肽治疗急性胰腺炎的效果分析

目的 研究乌司他丁联合奥曲肽治疗急性胰腺炎的临床效果.方法HT6K 选择2013年1月~2015年12月在我院进行诊治的急性胰腺炎患者100例,随机分为观察组与对照组,每组各50例.对照组采用乌司他丁治疗,观察组采用乌司他丁联合奥曲肽治疗,比较两组的临床治疗效果.结果 观察组的有效率为90.00%(45/50),明显高于对照组的76.00%(3850)(P<0.05).结论HT6K 乌司他丁联合奥曲肽对急性胰腺炎具有显著的临床效果,值得应用推广.     

乌司他丁联合奥曲肽治疗急性重症胰腺炎的疗效观察

目的探索乌司他丁联合奥曲肽治疗急性重症胰腺炎临床治疗效果。方法研究选择本院2015年5月至2019年5月收治的75例急性重症胰腺炎患者作为研究对象,按照随机分组方法将研究对象分为两组,对照组选择奥曲肽治疗,观察组选择乌司他丁联合奥曲肽治疗,观察两组患者的临床症状。结果观察组患者有效率为97.37%,对照组总有效率81.08%,可见观察组临床治疗效果明显,对比差异显著(P<0.05);观察组患者两组患者CTSI评分和Ranson评分明显低于对照组,两组对比差异显著(P <0.05);治疗前观察组白细胞计数、C反应蛋白(CRP)和血清淀粉酶AMS等指标与对照组相近,对比无差异(P> 0.05);治疗后血清指标均明显下降,且观察组血清指标明显低于对照组患者,两组对比差异显著(P <0.05)。结论乌司他丁联合奥曲肽治疗急性重症胰腺炎临床治疗效果较好,明显提升治疗有效率,改善患者临床症状和血清指标,具有临床推广价值。     

国家食品药品监督管理局国家药品标准修订件——注射用醋酸奥曲肽

为保证注射用醋酸奥曲肽安全有效、质量可控,现对《中国药典》2010版(二部)注射用醋酸奥曲肽标准中含量限度表示方法、酸度计溶液的澄清度与颜色等项进行修订。     

Octreotide and Potassium Homeostasis

Somatostatin infusion causes hyperkalemia in healthy subjects and in some animal models. The purpose of this investigation was to determine what effect octreotide has on potassium homeostasis during serious illness and if there is a dose-response relationship. Sixty-six male Sprague-Dawley rats (185–225 g) were randomized to receive parenteral nutrition (PN) only, PN plus continuous infusion of Escherichia coli lipopolysaccharide (LPS), or PN plus LPS plus octreotide 10, 100, or 1000 μg/kg/day for 48 hours. Before randomization all animals received isocaloric, isonitrogenous, isokalemic PN. A 24-hour urine was collected and a blood sample was taken at the end of the study immediately before euthanization. Data were analyzed by ANOVA and Duncan's multiple range test. Nonhemolyzed serum samples from 50 rats were available for study. Serum potassium concentrations were in the normal range for rats and did not differ significantly among the groups: 5.97 ± 0.86, 5.96 ± 1.58, 5.78 ± 1.48, 5.79 ± 1.67, 5.35 ± 0.78 mEq/L, respectively. No differences among groups were found for fractional excretion of potassium or serum creatinine concentration. Octreotide administration in escalating dosages does not cause hyperkalemia in endotoxemic rats given intravenous potassium at a constant rate by PN.     

Octreotide long-acting repeatable for acromegaly

Acromegaly remains a therapeutic challenge for the endocrinologist. Among the available therapeutic options, octreotide long-acting repeatable (Sandostatin(?) LAR(?), Novartis) plays a chief role, both as a primary therapy and as an adjuvant treatment after unsuccessful surgery. A plethora of papers and a meta-analysis have demonstrated its efficacy in: control of clinical picture; achievement of safe growth hormone and normal age-matched IGF-I levels (both factors associated with restoration of normal life expectancy) in 60-70% of patients; control of tumor volume (with real shrinkage in over half of cases); and halt or reversal of most acromegaly-associated comorbidities. Treatment is well tolerated in most patients and can be safely prolonged for many years if required.     

Octreotide, a new somatostatin analogue

The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects and drug interactions, dosage, availability and cost, and indications for use of octreotide, a new synthetic analogue of the peptide hormone somatostatin (SS), are reviewed. Like SS, octreotide suppresses secretion of pituitary growth hormone (GH) and thyrotropin and decreases release of a variety of pancreatic islet cell hormones including insulin, glucagon, and vasoactive intestinal peptide (VIP). Octreotide also reduces splanchnic blood flow, gastric acid secretion, GI motility, and pancreatic exocrine function and alters the absorption of water, electrolytes, and nutrients from the GI tract. The elimination half-life of i.v. octreotide is 72-98 minutes, compared with 2-3 minutes for i.v. SS. Usual administration of octreotide is by the i.v. or s.c. route. Octreotide has been studied in the treatment of hormone-secreting pituitary tumors and pancreatic islet cell tumors. Octreotide therapy lowers GH secretion and improves clinical symptoms in patients with acromegaly and may suppress clinical symptoms to a greater degree than bromocriptine. Patients with carcinoid syndrome and VIP-secreting tumors (vipomas) have had substantial improvement in clinical symptoms with administration of octreotide. This agent does not appear to be effective in the treatment of nonvariceal upper GI bleeding and acute pancreatitis; its relative usefulness in the treatment of variceal bleeding is not established. Adverse effects associated with octreotide therapy generally have been mild, including pain or burning at the injection site, abdominal pain, and diarrhea. Octreotide has been shown to interfere with absorption of oral cyclosporine. Standard initial therapy is octreotide acetate 50-100 micrograms s.c. every 8-12 hours, with titration based on clinical and biochemical effects. Up to 3000 micrograms/day of octreotide acetate has been administered to patients with acromegaly without serious adverse effect. Octreotide is marketed under the brand name Sandostatin and is available in 1-mL ampuls containing 50, 100, and 500 micrograms of octreotide acetate. Because the conditions for which octreotide appears to be most effective are uncommon, the drug should be considered for addition to the formulary in tertiary-care institutions only; addition of octreotide to the formulary of a community hospital is probably unnecessary. The synthetic analogue octreotide is longer acting and more specific in pharmacologic action than SS.(ABSTRACT TRUNCATED AT 400 WORDS)     

前列地尔联合奥曲肽治疗肝肾综合征

目的探讨前列地尔联合奥曲肽治疗肝肾综合征疗效。方法对2008年1月至2013年10月42例肝肾综合征患者随机分为治疗组和对照组,两组均同时采用基础治疗加前列地尔10μg/d。治疗组在对照组的基础上加用奥曲肽0.1 mg ih q8h/d,观察患者的临床症状、腹水减少情况以及肾功能指标。结果治疗组总有效率(71.43%)、腹水减少及肾功能好转均明显优于对照组(38.10%)(P<0.05)。结论前列地尔联合奥曲肽治疗肝肾综合征疗效明显优于前列地尔。     

奥曲肽治疗上消化道出血的疗效观察

目的观察奥曲肽治疗上消化道出血的疗效。方法选取2008年10月—2011年5月我科收治的40例上消化道出血住院患者,随机分为治疗组与对照组,每组各20例。对照组给予奥美拉唑治疗,治疗组在对照组基础上应用奥曲肽治疗,观察两组止血时间、输血量和再输血发生情况,并比较两组疗效。结果治疗组止血时间短于对照组,输血量少于对照组,差异有统计学意义(P<0.05),治疗组总有效率为90.0%,高于对照组的75.0%,差异有统计学意义(P<0.05)。治疗组再出血1例(10.0%),对照组为4例(20.0%),两组比较差异有统计学意义(P<0.05)。结论常规治疗基础上联用奥曲肽治疗急性上消化道出血能缩短止血时间,减少输血量和降低再出血率,应用安全有效。     

奥曲肽治疗急性胰腺炎

目的：观察奥曲肽治疗急性胰腺炎的效果。方法：４３例急性胰腺炎病人分成２组，皆用常规疗法，治疗组２１例加用奥曲肽１００μｇ，ｓｃ，随后６００μｇ溶于５％葡萄糖液１０００ｍＬ中静脉滴注２４ｈ，２组病例都观察腹痛时间、哌替啶总用量、检测胰腺水肿变化及记录血液主要生化指标。结果：治疗组无死亡及外科手术病例，哌替啶总用量仅７０±２７ｍｇ，腹痛缓解及胰腺水肿改善所需时间分别是１．２±０．５ｄ和８．５±２．０ｄ，血淀粉酶恢复正常时间明显优于对照组。用药过程未发现明显不良反应。结论：在常规疗法基础上加奥曲肽对治疗胰腺炎明显有效。     

奥曲肽治疗肠梗阻疗效的Meta分析

目的:评价奥曲肽治疗肠梗阻的临床疗效.方法:全面搜集以奥曲肽疗法治疗肠梗阻相关的随机对照或半随机对照临床试验文献,对入选文献进行Jadad评分、质量评价,运用Review Manager 5.0统计相关数据作异质性检验、敏感性分析、Mete分析、漏斗图分析,得出系统评价.结果:9篇文献符合纳入标准,共595例患者.Me...     

乌司他丁和奥曲肽联用治疗急性胰腺炎疗效观察

目的探讨乌司他丁与奥曲肽联合治疗急性胰腺炎的疗效。方法76例急性胰腺炎患者随机分为治疗组(乌司他丁和奥曲肽联用)(n=40)、对照组(单用奥曲肽)(n=36)。分别观察两组治疗后症状缓解、体征减轻、血尿淀粉酶(AMS)下降时间、并发症情况及住院时间。结果乌司他丁和奥曲肽联用能更快缓解临床症状及控制病情,缩短治疗时间。结论乌司他丁和奥曲肽联用治疗急性胰腺炎,疗效优于单用奥曲肽。     

奥曲肽治疗食道胃底静脉曲张破裂出血的疗效

目的 观察奥曲肽治疗肝硬化患者食管胃底静脉曲张破裂出血的疗效.方法 将56例患者随机分为治疗组和对照组,各28例;治疗组使用奥曲肽,对照组使用垂体后叶素,于治疗12、24、48、72h后观察止血率、再出血率、不良反应发生率及死亡率.结果 治疗组在不同时间点的止血率明显高于对照组(P＜0.01),而再出血率、不良反应发生率及死亡率均显著低于对照组(P＜0.01).结论 奥曲肽可显著降低患者的出血和死亡率,其不良反应发生率也显著降低,是控制肝硬化患者食管胃底静脉曲张破裂出血的有效药物.